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Objective: There are no universally successful guidelines for the treatment of metronidazole-resistant
vaginal trichomoniasis. This is distressing for patients and frustrating for physicians. We therefore
decided to evaluate whether zinc sulfate douche is effective in treating vaginal trichomoniasis, because
the compound is a natural antimicrobial chemical defense in humans.
Case reports: In our retrospective case review, eight cases of metronidazole-resistant trichomoniasis
were treated with 1% zinc sulfate douche with or without tinidazole between 2005 and 2012. Except for
one patient who was pregnant, seven patients were successfully treated and were negative for micro-
scopic ﬁndings with no clinical symptoms at follow up.
Conclusion: Although the exact role of zinc sulfate in metronidazole-resistant trichomoniasis is not clear,
our patients experienced a therapeutic effect with zinc sulfate douche treatment. We therefore recom-
mend zinc sulfate douche as an option for the treatment of metronidazole-resistant vaginal
trichomoniasis.
Copyright © 2015, Taiwan Association of Obstetrics & Gynecology. Published by Elsevier Taiwan LLC. All
rights reserved.Introduction
Trichomoniasis is caused by the protozoan parasite Trichomonas
vaginalis [1], which was ﬁrst discovered in 1836 by the European
physician Alfred Donne [2]. The annual incidence of trichomoniasis
worldwide is estimated to be approximately 248 million cases,
which makes it the most common nonviral sexually transmitted
disease [3]. Among women of reproductive age in the United States,
the prevalence of T. vaginalis infection is 3.1e8.7% [4,5]. Risk factors
for T. vaginalis infection in adult women include poverty, lower
educational level, douching, concurrent chlamydial infection, non-
Hispanic black race/ethnicity, a greater number of lifetime sex
partners, and older age [4,6,7]. Approximately 50e60% of
T. vaginalis infections in women are asymptomatic [8]. The most
common symptom is malodorous vaginal discharge [9]. Other
symptoms include dyspareunia, dysuria, lower abdominal pain, ore of Medicine, Inje University,
, South Korea.
ong).
bstetrics & Gynecology. Publishedvulvovaginal irritation [10,11]. Common signs include vulvovaginal
erythema, edema, frothy yellowish-gray or green vaginal discharge,
elevated pH (>6), and rarely a strawberry cervix [12]. Associated
complications of vaginitis caused by T. vaginalis include pelvic in-
ﬂammatory disease; cervical dysplasia; and perinatal complica-
tions such as preterm birth, premature rupture of membranes, and
low-birth-weight infants [11].
Metronidazole was introduced for the treatment of trichomo-
niasis in 1959 [13]. The cure rate for a single 2-g dose of oral
metronidazole is 90e95% [14]. Another recommended regimen for
trichomoniasis is a single 2-g dose of tinidazole, which has resulted
in cure rates of approximately 86e100% [14]. Low-level metroni-
dazole resistance has been reported in 2e5% of vaginal trichomo-
niasis cases [15,16]. Metronidazole resistance is clinically deﬁned as
a failure to cure infection after two consecutive courses of treat-
ment [17]. Once other causes of treatment failure, including rein-
fection and medication noncompliance have been ruled out, the
possibility of a resistant vaginal trichomoniasis must be considered
[18]. Although various therapeutic regimens have been attempted
and reported, there is no consensus on therapy for metronidazole-
resistant vaginal trichomoniasis [19].by Elsevier Taiwan LLC. All rights reserved.
Table 1
Case histories of seven patients.
Case 2 Case 3 Case 4 Case 5 Case 6 Case 7 Case 8
Age (y) 39 28 41 45 28 25 20
Duration of infection (mo) 3 3 18 12 24 5 3
Contraception (before
treatment)
None None None None OC OC None
Treatment before referral High-dose oral
metronidazole
500-mg oral
metronidazole b.i.d. for
7 d, three courses
IV metronidazole, oral
ornidazole,
metronidazole vaginal
pessary
High-dose oral
metronidazole
High-dose oral
metronidazole and
high-dose tinidazole
High-dose oral
metronidazole and
vaginal gel
High-dose oral
metronidazole
Sexual history No sexual relationship with
husband since onset of
symptoms
No sexual relationship
with husband since
onset of symptoms
No sexual relationship
with husband since
failure of treatment
No sexual relationship
since failure of
treatment
No sexual relationship
with partner since
onset of symptoms
No sexual relationship
with partner for 5 mo
No sexual relationship with
partner since onset of
symptoms
Diagnostic methods Microscopy test Microscopy test Microscopy test Microscopy test Microscopy test Microscopy test Microscopy test
Treatment before zinc
sulfate douching
500-mg oral tinidazole b.i.d.
for 19 d þ gyno Betadine
vaginal tab for 19 d
2-g oral metronidazole
for 4 d
500-mg oral tinidazole
b.i.d. for 21 d þ gyno
Betadine vaginal tab for
14 d
1000-mg oral
tinidazole b.i.d. þ gyno
Betadine vaginal tab for
28 d
No treatment 2-g oral tinidazole for
7 d
2-g oral tinidazole and
amoxicillin þ gyno
Betadine vaginal tab for 7 d
Duration of 1% zinc sulfate
douching (d)
28 14 14 14 27 25 21
Combined therapy No No 2-g oral tinidazole 2-g oral tinidazole 2-g oral tinidazole 2-g oral tinidazole 2-g oral tinidazole
Interval of ﬁrst case review
after 1% zinc sulfate
douching and ﬁndings
1 mo,
clinical improvement and
negative microscopy
1 wk,
clinical improvement
and negative
microscopy
3 wk,
positive microscopy
/second course of
treatment included 1%
zinc sulfate douching
with tinidazole
1 wk,
clinical improvement
and negative
microscopy
2 wk,
clinical improvement
and negative
microscopy
2 wk,
clinical improvement
and negative
microscopy
2 wk
clinical improvement and
negative microscopy
Last follow up 5 y 2 mo 4 mo 3 mo 6 mo 6 mo 3 mo
Recurrence No No Yes No No No No
b.i.d. ¼ 2 times/d; IV ¼ intravenous; OC ¼ oral contraceptive.
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which has a therapeutic effect on metronidazole-resistant vaginal
trichomoniasis.
Case Reports
Case 1
A 29-year-old woman, gravida 0, para 0, was referred for
treatment of 1-year persistent T. vaginalis infection, which caused
persistent malodorous vaginal discharge with irritation and
dysuria. She denied any sexual contact since these symptoms
began. Before referral, she previously received several courses of
metronidazole and tinidazole, both at standard and high dosages by
intravenous and oral routes. On the day of her initial visit to our
hospital, a yellowish-green vaginal discharge was present and
trichomonads were visualized under saline wet mount examina-
tion. She did not have co-infections such as Mycoplasma, Ure-
aplasma, and Chlamydia. She was treated with 1% zinc sulfate
douching 2 times/d for 14 days with concomitant oral tinidazole
500 mg 2 times/d for 12 days. She then used only the zinc sulfate
douchewithout the tinidazole for 7 days. Apart frommild irritation,
she tolerated the treatment well. Follow up was performed
monthly for 3 months after treatment, and then once every 3
months, with wet mount and physical examination. There was no
evidence of infection. The patient remained asymptomatic for the
following 3 months, at the end of which her case was reviewed.
Subsequently, she returned to her hometown.
Cases 2e8
Table 1 presents the data on seven patients who had a history of
3 months to 2 years of symptomatic vaginal trichomoniasis and
received a variety of therapies before referral. Six of them received
high-dose oral metronidazole or tinidazole therapy for 4e28 days
after referral. They did not respond to this therapy.
Subsequently, two of them were treated with single 1% zinc
sulfate douches, and the others were treated with a combination of
1% zinc sulfate douching and oral tinidazole for 14e28 days. All of
our patients experienced clinical improvement, lasting for days or
weeks, with a negative vaginal wet smear. The interval of follow up
was weekly for 1e2 months and then monthly for 3e6 months. At
the case review from 2 months to 5 years after therapy, six of the
seven patients remained asymptomatic and the results of clinical
and laboratory examinations were normal. Only one patient pre-
sented with a recurrence, which occurred 4 months after treat-
ment. She was not eligible to receive additional 1% zinc douche
treatment because of pregnancy.
Discussion
Metronidazole-resistant vaginal trichomoniasis is considered
rare but remains a major therapeutic challenge to physicians. It is
associated with signiﬁcant patient suffering and reduction of the
quality of life. The mechanisms that lead to such a refractory
response are unclear. Inactivation of metronidazole by vaginal
bacteria, ineffective delivery of the drug to the vaginal area, lack of
absorption of the medication [20], and low zinc concentrations in
serum [21] have been proposed as possible explanations for treat-
ment failure.
T. vaginalis seems to respond to sudden environmental changes
(e.g., temperature, microﬂora, pH, iron, polyamines, zinc, host im-
mune responses, and other unknown factors) [22]. Trichomoniasis
mostly affects women; in the case of men, most are cured rapidly of
the infection, suggesting that these sex variations may be related todifferences in the urogenital microenvironments affecting the
pathobiology of trichomonads. The zinc-rich environment in the
prostatic glands creates hostile conditions for T. vaginalis to survive.
Zinc is a known antimicrobial chemical defense in humans; men
with zinc concentrations >1.6mM in their prostatic secretions can
suffer chronic prostatitis due to T. vaginalis infection [23]. The
normal concentration of zinc (4.5e7mM) in the prostatic ﬂuid of
the majority of men has a trichomonacidal effect that helps to limit
or resolve this infection [23]. However, zinc concentrations similar
to those found in men with chronic prostatitis (<1.6mM) are not
trichomonacidal, and allow the parasite to survive in the prostatic
gland, causing a nonspeciﬁc acute inﬂammation [23]. Vazquez
Carrillo et al [24] reported that Znþ alters trichomonal virulence by
affecting its morphology, proteome, and expression of several of its
virulence factors when the DU145 prostatic cell line is used as a
host cell.
In the presented report, a retrospective case review identiﬁed
eight cases of metronidazole-resistant trichomonas between 2005
and 2012. In the absence of resistance testing, resistance was
deﬁned clinically. Patients received 1% zinc douche with or without
oral tinidazole for 14e28 days. All of our patients experienced
clinical improvement, lasting for days or weeks, with a negative
vaginal wet smear. At their last review, seven patients remained
symptom free with normal clinical examination results and nega-
tive wet mount, and only one patient presented with a recurrent
infection. We did not re-administer zinc sulfate douche to the pa-
tient with the recurring infection because she was pregnant at the
time. In rare cases, zinc sulfate douche was described to cause mild
cervical ulcer; thus, we avoided its use during pregnancy. Although
the exact role of zinc sulfate douche is uncertain, the therapeutic
effect of zinc was clearly achieved in our patients.
This study has several limitations. Our investigation was a
retrospective medical record review rather than a prospective
evaluation. In addition, in vitro susceptibility tests to metronidazole
or tinidazole in patients were not carried out. However, we believe
that zinc sulfate therapy merits further independent evaluation.
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